Wall Street brokerages expect Bristol-Myers Squibb Company (NYSE:BMY) to post earnings of $0.75 per share for the current quarter, according to Zacks. Five analysts have issued estimates for Bristol-Myers Squibb’s earnings, with the lowest EPS estimate coming in at $0.70 and the highest estimate coming in at $0.78. Bristol-Myers Squibb reported earnings per share of $0.77 in the same quarter last year, which suggests a negative year-over-year growth rate of 2.6%. The business is scheduled to report its next quarterly earnings results before the market opens on Thursday, October 26th.

On average, analysts expect that Bristol-Myers Squibb will report full year earnings of $2.98 per share for the current financial year, with EPS estimates ranging from $2.95 to $3.00. For the next fiscal year, analysts expect that the company will post earnings of $3.12 per share, with EPS estimates ranging from $2.91 to $3.23. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the company posted $0.69 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year.

Several equities research analysts have recently weighed in on BMY shares. Jefferies Group LLC reissued a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, June 5th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective for the company in a research report on Monday, June 5th. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 26th. Finally, Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $62.31.

ILLEGAL ACTIVITY NOTICE: “$0.75 Earnings Per Share Expected for Bristol-Myers Squibb Company (BMY) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/14/0-75-earnings-per-share-expected-for-bristol-myers-squibb-company-bmy-this-quarter.html.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank increased its stake in Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after buying an additional 162,884 shares during the period. Mutual of America Capital Management LLC increased its stake in Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after buying an additional 3,833 shares during the period. Meridian Management Co. increased its stake in Bristol-Myers Squibb by 1.5% in the 1st quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock valued at $2,815,000 after buying an additional 770 shares during the period. Tobam increased its stake in Bristol-Myers Squibb by 124.5% in the 1st quarter. Tobam now owns 793,714 shares of the biopharmaceutical company’s stock valued at $43,163,000 after buying an additional 440,170 shares during the period. Finally, Quantitative Investment Management LLC acquired a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $6,150,000. Hedge funds and other institutional investors own 68.80% of the company’s stock.

Bristol-Myers Squibb (NYSE:BMY) traded up 0.33% during trading on Thursday, reaching $62.69. 4,603,784 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $57.94 and a 200 day moving average price of $55.81. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $63.47. The stock has a market capitalization of $102.80 billion, a P/E ratio of 22.89 and a beta of 1.18.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.49%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.